Pfizer Inc., the world’s largest drugmaker, rose to its highest price in more than four years after Goldman Sachs Group Inc. analysts said the company may go beyond the divestiture plans it has already announced.
Drugmaker executives whose companies promote unauthorized uses of their medicines may be targeted by U.S. regulators for misdemeanor prosecutions, Food and Drug Administration Deputy Chief for Litigation Eric Blumberg said.
Jeffrey Kindler resigned as Pfizer Inc. ’s chief executive officer after he refused to name a head of operations as part of a plan agreed to by senior managers in September, said a person familiar with the proceedings.
Eli Lilly & Co. , under pressure to gain new products after setbacks this week with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc. or covet companies with more approved products.
Jeffrey Kindler ’s refusal to name an operations chief in response to a push from senior managers cost him his job as chief executive officer of Pfizer Inc., according to a person familiar with the process.